Terms: = Kidney tumors AND EPS15, AF-1P, 2060, ENSG00000085832, P42566, MLLT5, AF1P AND Treatment
4 results:
1. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza B; Frangou E; Smith B; Bryant H; Kaplan R; Choodari-Oskooei B; Powles T; Stewart GD; Albiges L; Bex A; Choueiri TK; Davis ID; Eisen T; Fielding A; Harrison D; McWhirter A; Mulhere S; Nathan P; Rini B; Ritchie A; Scovell S; Shakeshaft C; Stockler MR; Thorogood N; Parmar MKB; Larkin J; Meade A
Contemp Clin Trials; 2021 Sep; 108():106482. PubMed ID: 34538402
[TBL] [Abstract] [Full Text] [Related]
2. Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
Wabbijn M; Balk AH; van Domburg RT; Vantrimpont PJ; van Riemsdijk IC; Baan CC; Weimar W; van Gelder T
Exp Clin Transplant; 2004 Jun; 2(1):201-7. PubMed ID: 15859929
[TBL] [Abstract] [Full Text] [Related]
3. [Nephrogenic adenoma of the urinary bladder. A lesion that can be confused with carcinoma. Report of 4 cases].
RodrÃguez-Montes CE; Alvarado-Cabrero I
Gac Med Mex; 2001; 137(1):67-72. PubMed ID: 11244829
[TBL] [Abstract] [Full Text] [Related]
4. Enolase isozymes as markers for differential diagnosis of neuroblastoma, rhabdomyosarcoma, and Wilms' tumor.
Ishiguro Y; Kato K; Ito T; Horisawa M; Nagaya M
Gan; 1984 Jan; 75(1):53-60. PubMed ID: 6327451
[TBL] [Abstract] [Full Text] [Related]
